Non-alcoholic fatty liver disease (NAFLD) has been emerging as the leading chronic liver disease and a significant global health burden gradually, affecting up to 25% of the world population. In China, the prevalence of NAFLD reached 32.9% in 2018. And the incidence has risen substantially over the past decades, from 4.6% in 2011-2013 to 5.2% in 2014-2016. NAFLD, ranging from isolated hepatic steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis, is viewed as the hepatic manifestation of metabolic syndrome. The progression of NAFLD is often unpredictable and asymptomatic, which makes it easy to be ignored. Therefore, it is necessary to identify new biomarkers in terms of the prediction of the occurrence and development of NAFLD.